Trastuzumab emtansine in HER2-positive metastatic breast cancer

Affiliations

¹ Investigative Clinical Oncology, Fondazione del Piemonte per l'Oncologia, Candiolo Cancer Institute, 10060 Candiolo, Torino, Italy. Electronic address: filippo.montemurro@ircc.it.

Comment

Filippo Montemurro. Lancet Oncol. 2017 Jun.

. 2017 Jun;18(6):696-697.

doi: 10.1016/S1470-2045(17)30303-0. Epub 2017 May 16.

¹ Investigative Clinical Oncology, Fondazione del Piemonte per l'Oncologia, Candiolo Cancer Institute, 10060 Candiolo, Torino, Italy. Electronic address: filippo.montemurro@ircc.it.

No abstract available

Comment on

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, Green M, Gianni L. Diéras V, et al. Lancet Oncol. 2017 Jun;18(6):732-742. doi: 10.1016/S1470-2045(17)30312-1. Epub 2017 May 16. Lancet Oncol. 2017. PMID: 28526536 Free PMC article. Clinical Trial.
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, Hoersch S, Smitt M, Wildiers H. Krop IE, et al. Lancet Oncol. 2017 Jun;18(6):743-754. doi: 10.1016/S1470-2045(17)30313-3. Epub 2017 May 16. Lancet Oncol. 2017. PMID: 28526538 Clinical Trial.